Efficient immuno-modulation of TH1/TH2 biomarkers in 2,4-dinitrofluorobenzene-induced atopic dermatitis: Nanocarrier-mediated transcutaneous co-delivery of anti-inflammatory and antioxidant drugs

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Hussain, Zahid ^a   Katas, Haliza ^a   Amin, Mohd Cairul Iqbal Mohd ^a   Kumolosasi, Endang ^a  

^a UNIVERSITI KEBANGSAAN MALAYSIA   (Malaysia)

Author keywords

[No Author keywords available]

Indexed keywords

1 FLUORO 2,4 DINITROBENZENE; BIOLOGICAL MARKER; HISTAMINE; HYDROCORTISONE; HYDROXYTYROSOL; IMMUNOGLOBULIN E; NANOCARRIER; PROSTAGLANDIN E2; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL GROWTH FACTOR ALPHA; VASCULOTROPIN; 3,4-DIHYDROXYPHENYLETHANOL; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; CYTOKINE; DRUG CARRIER; NANOPARTICLE; PHENETHYL ALCOHOL; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATOPIC DERMATITIS; BLOOD SAMPLING; CELL INFILTRATION; COLLAGEN FIBER; COLLAGEN FIBER DEPOSITION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG FORMULATION; ELASTIC FIBER; EX VIVO STUDY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; IN VIVO STUDY; MOUSE; NONHUMAN; PARTICLE SIZE; PH MEASUREMENT; PHYSICAL CHEMISTRY; SKIN BIOPSY; SKIN FIBROBLAST; SKIN FIBROSIS; SKINFOLD THICKNESS; TH1 CELL; TH2 CELL; TISSUE METABOLISM; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; CHEMICALLY INDUCED; CHEMISTRY; DERMATITIS, ATOPIC; DISEASE MODEL; IMMUNOLOGY; INTRADERMAL DRUG ADMINISTRATION; METABOLISM; PATHOLOGY; SKIN;

ADMINISTRATION, CUTANEOUS; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; BIOMARKERS; CYTOKINES; DERMATITIS, ATOPIC; DINITROFLUOROBENZENE; DINOPROSTONE; DISEASE MODELS, ANIMAL; DRUG CARRIERS; HISTAMINE; HYDROCORTISONE; IMMUNOGLOBULIN E; MICE; NANOPARTICLES; PHENYLETHYL ALCOHOL; SKIN; TH1 CELLS; TH2 CELLS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84911934880     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0113143     Document Type: Article

References (43)

1. Grewe M, Bruijnzeel-Koomen CA, Schopf E (1998) A role for Th1 and Th2 cells in the immunopathogenesis of atopic dermatitis. Immunology Today 19: 359-361.
2. Leung DY (2000) Atopic dermatitis: new insights and opportunities for therapeutic intervention. J Allergy Clin Immunol 105: 860-876.
3. Hussain Z, Katas H, Amin MCIM, Kumolosasi E, Buang F, et al. (2013) Self assembled polymeric nanoparticles for percutaneous co-delivery of hydrocortisone/hydroxytyrosol: an ex vivo and in vivo study using an NC/Nga mouse model. Int J Pharm 444: 109-119.
4. Leung DY, Bieber T (2003) Atopic dermatitis. Lancet 361: 151-160.
5. Abramovits W (2005) Atopic dermatitis. J Am Acad Dermatol 53: S86-S93.
6. Wuthrich B, Cozzio A, Roll A, Senti G, Kundig T, et al. (2007) Atopic eczema: genetics or environment? Ann Agric Environ Med 14: 195-201.
7. Zhang Y, Matsuo H, Morita E (2006) Increased production of vascular endothelial growth factor in the lesions of atopic dermatitis. Arch Dermatol Res 297: 425-429.
8. Jung MK, Hur DY, Song SB, Park Y, Kim TS, et al. (2010) Tannic acid and quercetin display a therapeutic effect in atopic dermatitis via suppression of angiogenesis and TARC expression in Nc/Nga mice. J Investig Dermatol 130: 1459-1463.
9. Kang MJ, Eum JY, Park SH, Kang MH, Park KH, et al. (2010) Pep-1 peptide-conjugated elastic liposomal formulation of taxifolin glycoside for the treatment of atopic dermatitis in NC/Nga mice. Int J Pharm 402: 198-204.
10. Lee HS, Kim SK, Han JB, Choi HM, Park JH, et al. (2006) Inhibitory effects of Rumex japonicus Houtt on the development of atopic dermatitis-like skin lesions in NC/Nga mice. Br J Dermatol 155: 33-38.
11. Alomar A, Berth-Jones J, Bos JD (2004) The role of topical calcineurin inhibitors in atopic dermatitis. Br J Dermatol 151: 3-27.
12. Şenyiʇit T, Padula C, Özer Ö, Santi P (2009) Different approaches for improving skin accumulation of topical corticosteroids. Int J Pharm 380: 155-160.
13. Schoepe S, Schacke H, May E, Asadullah K (2006) Glucocorticoid therapy-induced skin atrophy. Exp Dermatol 15: 406-420.
14. Zöller NN, Kippenberger S, Thac¸i D, Mewes K, Spiegel M, et al. (2008) Evaluation of beneficial and adverse effects of glucocorticoids on a newly developed full-thickness skin model. Toxicol In Vitr 22: 747-759.
15. Moser K, Kriwet K, Naik A, Kalia YN, Guy RH (2001) Passive skin penetration enhancement and its quantification in vitro. Eur J Pharm Biopharm 52: 103-112.
16. Godwin DA, Kim NH, Felton LA (2002) Influence of Transcutol CG on the skin accumulation and transdermal permeation of ultraviolet absorbers. Eur J Pharm Biopharm 53: 23-27.
17. Sammeta S, Vaka S, Murthy S (2010) Transcutaneous electroporation mediated delivery of doxepin-HPCD complex: a sustained release approach for treatment of postherpetic neuralgia. J Control Release 142: 361-367.
18. Prausnitz M (2004) Microneedles for transdermal drug delivery. Adv Drug Deliv Rev 56: 581-587.
19. Couvreur P, Dubernet C, Puisieux F (1995) Controlled drug delivery with nanoparticles: current possibilities and future trends. Eur J Pharm Biopharm 41: 2-13.
20. Trotta M, Peira E, Debernardi F, Gallarate M (2002) Elastic liposomes for skin delivery of dipotassium glycyrrhizinate. Int J Pharm 241: 319-327.
21. Fang YP, Huang YB, Wu PC, Tsai YH (2009). Topical delivery of 5-aminolevulinic acid-encapsulated ethosomes in a hyperproliferative skin animal model using the CLSM technique to evaluate the penetration behaviour. Eur J Pharm Biopharm 73: 391-398.
22. Jenning V, Gysler A, Schafer-Korting M, Gohla S (2000) Vitamin A-loaded solid lipid nanoparticles for topical use: occlusive properties and drug targeting to the upper skin. Eur J Pharm Biopharm 49: 211-218.
23. Huailiang W, Chandrasekharan R, Norman DW, Blake JR (2001) Topical transport of hydrophilic compounds using water-in-oil nanoemulsions. Int J Pharm 220: 63-75.
24. Lademann J, Richter H, Teichmann A, Otberg N, Blume-Peytavi U, et al. (2007) Nanoparticles-an efficient carrier for drug delivery into the hair follicles. Eur J Pharm Biopharm 66: 159-164.
25. Biruss B, Valenta C (2006) Skin permeation of different steroid hormones from polymeric coated liposomal formulations. Eur J Pharm Biopharm 62: 210-219.
26. Kuchler S, Radowski MR, Blaschke T, Dathe M, Plendl J, et al. (2009) Nanoparticles for skin penetration enhancement: a comparison of a dendritic core-multishell-nanotransporter and solid lipid nanoparticles. Eur J Pharm Biopharm 71: 243-250.
27. Hussain Z, Katas H, Mohd Amin MCI, Kumolosasi E, Sahudin S (2013) Antidermatitic Perspective of Hydrocortisone as Chitosan Nanocarriers: An Ex Vivo and In Vivo Assessment Using an NC/Nga Mouse Model. J Pharm Sci, 102: 1063-1075.
28. Clausen AE, Bernkop-Schnurch A (2001) Thiolated carboxymethylcellulose: in vitro evaluation of its permeation enhancing effect on peptide drugs. Eur J Pharm Biopharm 51: 25-32.
29. Papadimitriou S, Bikiaris D, Avgoustakis K (2008) Chitosan nanoparticles loaded with dorzolamide and pramipexole. Carbohyd Polym 73: 44-54.
30. Shu XZ, Zhu KJ (2002) The influence of multivalent phosphate structure on the properties of ionically cross-linked chitosan films for controlled drug release. Eur J Pharm Biopharm 54(2): 235-243.
31. Lippacher A, Muller RH, Mader K (2001) Preparation of semisolid drug carriers for topical application based on solid lipid nanoparticles. Int J Pharm 214: 9-12.
32. Almeida IF, Bahia MF (2006) Evaluation of the physical stability of two oleogels. Int J Pharm 327: 73-77.
33. Mei Z, Wu Q, Hu S, Li X, Yang X (2005) Triplicate Loaded Solid Liquid Nanoparticles Hydrogel for Topical Application. Drug Dev Ind Pharm 31(2): 181-168.
34. Contreras MD, Sanchez R (2002) Application of Factorial Design to the Study of the Flow Behavior, Spredabilityand Transparency of Carbopol ETD 2020, Part II. Int J Pharm 234(1-2): 140-157.
35. Izidoro DR, Scheer AP, Sierakowski MR, Haminiuk CWI (2008) Influence of green banana pulp on the rheological behavior and chemical characteristics of emulsions (mayonnaises). Food Sci Technol 41: 1018-1028.
36. El-Hefian EA, Elgannoudi ES, Mainal A, Yahaya AH (2010) Characterization of chitosan in acetic acid: Rheological and thermal studies. Turk J Chem 34: 47-56.
37. Park E, Park K, Eo H, Seo J, Son M, et al. (2007) Suppression of spontaneous dermatitis in NC/Nga murine model by PG102 isolated from Actinidia arguta. J Invest Dermatol 127: 1154-1160.
38. Kang MJ, Eum JY, Park SH, Kang MH, Park KH, et al. (2010) Pep-1 peptide-conjugated elastic liposomal formulation of taxifolin glycoside for the treatment of atopic dermatitis in NC/Nga mice. Int J pharm 402: 198-204.
39. Matsuda H, Watanabe N, Geba GP, Sperl J, Tsudzuki M, et al. (1997) Development of atopic dermatitis-like skin lesion with IgE hyperproduction in NC/Nga mice. Int Immunol 9: 461-466.
40. Galli SJ, Tsai M, Piliponsky AM (2008) The development of allergic inflammation. Nature 454: 445-54.
41. Şenyiʇit T, Padula C, Özer Ö, Santi P (2009) Different approaches for improving skin accumulation of topical corticosteroids. Int J Pharm 380: 155-160.
42. Tomimori Y, Tanaka Y, Goto M, Fukuda Y (2005) Repeated topical challenge with chemical antigen elicits sustained dermatitis in NC/Nga mice in specific-pathogen-free condition. J Invest Dermatol 124: 119-124.
43. Suda N, Yu X, Kubo C (2002) Dehydroepiandrosterone attenuates the spontaneous elevation of serum IgE level in Nc/Nga mice. Immunol Lett 79: 177-9.